Dinutuximab

Bartholomew, Joy; Washington, Tanea; Bergeron, Sharon; Nielson, Danelle; Saggio, Jennifer; Quirk, Lindsay

doi:10.1177/1043454216659448

Cited by 17 publications

(8 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The unclear pathogenesis of neuroblastoma impedes the development of therapeutic drugs discovery and effective tumor therapy. With decades of efforts, only Unituxin (dinutuximab) was approved by the US Food and Drug Administration as a novel targeted drug in 2015, which can prolong the survival of patients with high-risk NB [ 6 ]. Therefore, clear clarification of mechanisms underlying NB progression is urgently needed.…”

Section: Introductionmentioning

confidence: 99%

MiR-20a-5p suppresses tumor proliferation by targeting autophagy-related gene 7 in neuroblastoma

Zhang

Jin

et al. 2018

Cancer Cell Int

View full text Add to dashboard Cite

BackgroundNeuroblastoma (NB) is the most common malignant tumor originating from the extracranial sympathetic nervous system in children. The molecular mechanisms underlying this disease are complex, and not completely understood.MethodsQuantitative real-time PCR (qRT-PCR) was applied to quantify the expression of miR-20a-5p and its target gene ATG7 in clinical NB tissues. The biological function of miR-20a-5p and ATG7 in SH-SY5Y cells was investigated through in vitro studies (Real-Time cell kinetic analyzer, colony formation assay, caspase-Glo 3/7 assay and western blotting). The luciferase reporter assay was conducted to verify the biological relationship between miR-20a-5p and ATG7.ResultsHere we found that miR-20a-5p expression was significantly downregulated whereas its target autophagy-related gene 7 (ATG7) was increased along with clinical staging of NB progression. Correlation analysis showed that miR-20a-5p had a negative correlation trend with ATG7. In SH-SY5Y cells, forced expression of miR-20a-5p suppressed ATG7 expression, autophagy initiation and cellular proliferation while promoted apoptosis, suggesting a potential association between miR-20a-5p and ATG7. Further bioinformatic target prediction combined with protein expression and luciferase reporter assay verified that miR-20a-5p inhibited ATG7 by directly binding to its 3′-UTR, confirming the involvement of miR-20a-5p in the regulation of ATG7 in NB.ConclusionsThese results clarified that miR-20a-5p inhibited cell proliferation and promoted apoptosis through negative regulation of ATG7 and thus autophagy suppression in SH-SY5Y cells. Therefore, defining the context-specific roles of autophagy in NB and regulatory mechanisms involved will be critical for developing autophagy-targeted therapeutics against NB. Both miR-20a-5p and ATG7 would be potential therapeutic targets for future NB treatment.

show abstract

Section: Introductionmentioning

confidence: 99%

MiR-20a-5p suppresses tumor proliferation by targeting autophagy-related gene 7 in neuroblastoma

Zhang

Jin

et al. 2018

Cancer Cell Int

View full text Add to dashboard Cite

show abstract

“…The recommended gabapentin regimen varies for different anti-GD2 mAbs. For dinutuximab and dinutuximab beta, gabapentin administration starts 2 to 3 days before the infusion or on the day of infusion, 6,21,26 whereas for naxitamab infusions, gabapentin is initiated 5 days before the first infusion. 7 Gabapentin has also been used in combination with tricyclic antidepressants as premedication for anti-GD2 infusions; based on the authors' experience of using tricyclic antidepressants to treat neuropathic pain, desired effects are achieved after at least 2 days of continuous therapy.…”

Section: Gabapentin and Tricyclic Antidepressantsmentioning

confidence: 99%

Pain mitigation and management strategies for anti‐GD2 infusions: An expert consensus

Nysom

Morad

Rafael

et al. 2023

Pediatric Blood & Cancer

View full text Add to dashboard Cite

Monoclonal antibodies (mAbs) targeting disialoganglioside 2 (GD2) are an important treatment advance for high‐risk neuroblastoma, including in patients with refractory or relapsed disease. Dinutuximab and dinutuximab beta are administered for ≥8 hours (and up to 10 days for dinutuximab beta), whereas naxitamab is administered over 0.5 to 2 hours as tolerated. As acute pain is a class effect of anti‐GD2 mAbs, effective pain management is crucial to successful treatment. Here, we provide an overview of current pain‐management strategies for anti‐GD2 mAb infusions, with a focus on strategies suitable for naxitamab infusions, which cause a more rapid onset of often severe pain. We discuss opioid analgesics, ketamine, gabapentin, and other similar agents and nonpharmacologic approaches. Potential future pain‐management options are also discussed, in addition to the use of sedatives to reduce the anxiety that may be associated with infusion‐related pain. In this expert consensus paper, specific guidance for pain management during naxitamab infusions is provided, as these infusions are administered over 0.5 to 2 hours and may not need overnight hospitalization based on the physician's assessment, and require rapid‐onset analgesia options suitable for potential outpatient administration.

show abstract

“…Especially, IL-2 can cause serious adverse reactions such as fever, capillary leak syndrome, and infections. 33 Clinical studies showed that most of the adverse reactions are also seen in regimen containing only retinoic acid with low possibility. 17…”

Section: Dinutuximabmentioning

confidence: 99%

Dinutuximab in the Treatment of High-Risk Neuroblastoma in Children

Gür

Ozen

Saylan

et al. 2017

Clinical Medicine Insights: Therapeutics

View full text Add to dashboard Cite

Neuroblastoma is the most common extracranial tumor derived from neural crest cells in childhood, and treatment of high-risk neuroblastoma is a difficulty in oncology field. The discovery of new treatment strategies to treat pediatric patients with high-risk neuroblastoma is important. Dinutuximab (ch14.18; Unituxin), a chimeric human-mouse monoclonal antibody, is approved by Food and Drug Administration in 2015 to be used specifically in the treatment of high-risk neuroblastoma. It binds the disialoganglioside (GD2) antigen on the surface of neuroblastoma cells and induces lysis of GD2-expressed neuroblastoma cells via antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity. To enhance its activity, it is used with a combination of granulocyte-macrophage colony-stimulating factor, interleukin 2, and 13-cis-retinoic acid. In this review, we discuss the use of dinutuximab in the treatment of high-risk neuroblastoma.

show abstract

Dinutuximab

Abstract: Therapy combining dinutuximab with granulocyte macrophage colony stimulating factor, interleukin 2, and isotretinoin has significant side effects; however, these complications are generally predictable and can be managed proactively.

Cited by 17 publications

References 12 publications

MiR-20a-5p suppresses tumor proliferation by targeting autophagy-related gene 7 in neuroblastoma

MiR-20a-5p suppresses tumor proliferation by targeting autophagy-related gene 7 in neuroblastoma

Pain mitigation and management strategies for anti‐GD2 infusions: An expert consensus

Dinutuximab in the Treatment of High-Risk Neuroblastoma in Children

Contact Info

Product

Resources

About